June 2021 - PharmaTimes

June 2021 - PharmaTimes
Published on 2 June 2021

Description:

Cell and gene therapy trials, genetic sequencing, trends in global trials, RNA in the spotlight, pharma’s engagement with the NHS, medical cannabis, patenting shapes, virtual therapies, prescribing freedoms, interviews with Anthony Yanni and Young Leaders in healthcare comms, plus regulars

Categories:

PharmaTimes
35 articles from this collection:
Cover
Cover
2 - PharmaTimes Marketer of the Year 2021
2 - PharmaTimes Marketer of the Year 2021
3 - From the editor
3 - From the editor
This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020. Taking top-spot in the ranking, Exscientia has almost quadrupled its revenue in the last two years, a remarkable achievement and even more so considering the current climate. Turn to page 20 for an in-depth look at the other companies reaching new heights and what’s fuelling their success.
4-5 - Contents
4-5 - Contents
6 - PharmaTimes Sales Awards 2021
6 - PharmaTimes Sales Awards 2021
7 - NHS
7 - NHS
The UK government has unveiled plans for a new round of NHS reforms that aim to pave the way for health and care services to work more closely together, improve care and tackle health inequalities.
8 - Medicine News
8 - Medicine News
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the potential reclassification of two progestogen-only, oral contraceptive pills containing desogestrel: Lovima 75mcg and Hana 75mcg film-coated tablets.
9 - Hot or Not
9 - Hot or Not
ViiV Healthcare’s Rukobia (fostemsavir) has received a marketing authorisation in Europe for the treatment of adults with multidrug-resistant HIV-1 infection. The EU has cleared use of the drug in patients who cannot otherwise receive a suppressive antiviral-regimen. Rukobia – a first-in-class HIV attachment inhibitor – is designed to target the first step of the HIV life-cycle. According to ViiV, it shows no cross-resistance to other currently approved antiretroviral classes, offering a new option for patients who are multidrug-resistant and at a higher risk of disease progression or death.
10 - Industry News
10 - Industry News
11 - PharmaTimes Communications Awards 2021
11 - PharmaTimes Communications Awards 2021
12- Covid News
12- Covid News
The UK government is streaming funds of £18.5 million into four research projects striving to improve understanding of the longer-term effects of COVID-19, known as long COVID.
13 - YL - Lydia Oikonomidis
13 - YL - Lydia Oikonomidis
13 - YL - Nicole Corteen
13 - YL - Nicole Corteen
14 - YL - James Addicott
14 - YL - James Addicott
14 - YL - Rebecca Godfrey
14 - YL - Rebecca Godfrey
15 - YL - Lucy Goodwill
15 - YL - Lucy Goodwill
15 - YL - Robyn Wagner
15 - YL - Robyn Wagner
16-17 - (New) terms of engagement
16-17 - (New) terms of engagement
18-19 - Doctors in chains?
18-19 - Doctors in chains?
20-21 - Connecting the dots
20-21 - Connecting the dots
22-23 - RNA in  the spotlight
22-23 - RNA in the spotlight
24-25 - Past, present and future
24-25 - Past, present and future
26 - 28 - Keeping pace
26 - 28 - Keeping pace
The last decade has brought pharma and the NHS much closer, but while the union is often inspirational, it is also – like any long-term relationship – a bit complicated. Three experts discuss the future of the pharma-NHS dynamic.
29 - The Best of Business Intelligence 2021
29 - The Best of Business Intelligence 2021
30-31 - In the genes
30-31 - In the genes
32-33 - The shape of it
32-33 - The shape of it
Oli Hudson and Steve How, of Wilmington Healthcare, explore how NHS England’s new system-level funding works and the impact on prescribing for high cost drugs
34-35 - Breaking boundaries
34-35 - Breaking boundaries
36-37 - A different perspective
36-37 - A different perspective
The impact of COVID-19 in 2020 has had significant ramifications as healthcare professionals have had to switch focus to managing and controlling the virus, which has left a huge hole for patients with long-term conditions, such as cancer.
38-39 - The purity approach
38-39 - The purity approach
40-41 - The medical cannabis opportunity
40-41 - The medical cannabis opportunity
42-43 - Smart People: Anthony Yanni
42-43 - Smart People: Anthony Yanni
44-45 - Appointments
44-45 - Appointments
46 - Safety first
46 - Safety first
47 - PharmaTimes Clinical Researcher of the Year 2021 - The Americas
47 - PharmaTimes Clinical Researcher of the Year 2021 - The Americas
48 - MSC Mediterranean Shipping Company
48 - MSC Mediterranean Shipping Company